EMR Survey: Ivermectin Associated with Lower Mortality Than Remdesivir


Posted originally on TrialSite New by Staff March 5, 2022

EMR Survey Suggests Ivermectin Associated with Lower Mortality Than Remdesivir

A team of University of Miami researchers compared fatality rates for COVID-19 patients who took ivermectin and those who took remdesivir and found the ivermectin cohort experienced reduced mortality.

“Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir,” the authors wrote.

The authors determined that ivermectin’s odds ratio of mortality compared to Remdesivir was 0.308.

Ivermectin vs. Remdesivir

Ivermectin has been discouraged as an early treatment option by the United States Food and Drug Administration, Centers for Disease Control and other public health authorities, while remdesivir has been endorsed by those same authorities.

Subscribe to the Trialsitenews “COVID-19” Channel

No spam – we promise

“To our knowledge, this is the largest association study of patients with COVID-19, mortality and ivermectin,” said the authors. “Further double-blinded placebo-controlled [random controlled trials] with large samples are required for definite conclusion.”

University of Miami Research Team

The researchers included medical student Iakov Efimenko, medical student Sirpi NackeeranSinan K. Jabori, MD, Associate Program Director of the Infectious Disease Fellowship Jose Gonzalez Zamora, MDSara Danker, MD, and Devinder Singh, MD, all of whom are affiliated with University of Miami’s Miller School of Medicine.

TriNetX Research Network Searched 

The team searched patient records on the TriNetX Research network, a federated electronic medical records network of over 44 healthcare organizations and 68 million U.S. patients from 2009 to 2021 to identify adults with a recorded COVID-19 infection between January 1, 2020, and July 11, 2021. 

The team then compared those with recorded use of ivermectin, but not remdesivir, against those with recorded use of remdesivir, but not ivermectin. 

The team also controlled for comorbidities and treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use.

Mortality Primary Outcome

The group measured association with mortality as the primary outcome.

The team identified a cohort of 1,072 people who were treated with ivermectin and another 40,536 who were treated with remdesivir. 

In the ivermectin cohort, the average age was 51.9 + 17.8 years, 43% were male, 60% had glucocorticoids, and 1% required ventilator support, average age. 

In the remdesivir cohort, the average age was 62.0 + 16.0 years, 54% were male, 64% had glucocorticoids, and 2% required ventilator support. 

Ivermectin Reduced Mortality vs. Remdesivir by 70%

After using propensity score matching and adjusting for potential confounders, ivermectin was associated with 70 percent reduced mortality vs remdesivir with a risk difference of -5.224%.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.